Skip to main content

Day: December 13, 2020

ABO-GROUP acquires French engineering firm GEO+ Environnement.

Ghent, 13 December 2020, 5 p.m.Press release / Regulated informationABO-GROUP acquires French engineering firm GEO+ Environnement.ABO-GROUP will acquire all the shares of the French GEO+ Environnement company at the beginning of January 2021. GEO+ Environnement has its head offices in Gardouch, near Toulouse, in the French department of Haute-Garonne, and has four offices in Central, North, East and South-West France.Thanks to around 25 hydrogeologists, ecologists and geologists, the added expertise and knowledge in the mining, quarrying and dyke sectors can thereby also be offered to the other ABO-GROUP home countries.GEO+ Environnement is an independent consultancy specialised in environmental advice in the mineral industry (mines and quarries), with expertise in environment, geology and hydraulic engineering. It is the French reference...

Continue reading

ABO-GROUP neemt Frans ingenieursbureau GEO+ Environnement over

Gent, 13 december 2020, 17 uPersbericht / Gereglementeerde informatieABO-GROUP neemt Frans ingenieursbureau GEO+ Environnement over.ABO-GROUP verwerft begin januari 2021 alle aandelen van het Franse GEO+ Environnement. GEO+ Environnement heeft haar hoofdzetel in Gardouch, nabij Toulouse, in het Franse departement Haute-Garonne, met vier kantoren verspreid in het center, het Noorden, Oosten en Zuidwesten van Frankrijk.De toegevoegde expertise en kennis in de sector van mijnbouw, steengroeven en dijken kan dankzij een 25-tal hydrogeologen, ecologen en geologen, hierbij ook in de andere thuislanden van ABO-GROUP aangeboden worden.GEO+ Environnement is een onafhankelijk adviesbureau gespecialiseerd in milieuadvies in de minerale industrie (mijnen en steengroeven), met een expertise in milieu, geologie en waterbouw. Het is hét Frans referentiebureau...

Continue reading

ABO-GROUP acquiert la société française d’ingénierie GEO+ Environnement

Gand, le 13 décembre 2020, 17 heuresCommuniqué de presse / Information réglementéeABO-GROUP acquiert la société française d’ingénierie GEO+ Environnement.ABO-GROUP acquerra la totalité des actions de la société française GEO+ Environnement au début du mois de janvier 2021. GEO+ Environnement a son siège social à Gardouch, près de Toulouse, dans le département français de la Haute-Garonne, avec quatre bureaux dans le centre, le nord, l’est et le sud-ouest de la France.À la clef : une expertise et des connaissances supplémentaires dans le secteur des mines, des carrières et des digues qui pourront désormais être également proposées dans les autres pays d’activité d’ABO-GROUP, grâce à quelque 25 hydrogéologues, écologistes et géologues.GEO+ Environnement est un bureau d’études indépendant spécialisé dans le conseil environnemental...

Continue reading

TCR² Announces RECIST Response in Ovarian Cancer from Ongoing Phase 1/2 Trial of TC-210 in Treatment Refractory Mesothelin-Expressing Solid Tumors

– TC-210 induced tumor regression in all of the first eight patients– Ovarian cancer patient achieved confirmed RECIST partial response (PR)– Overall response rate (ORR) 50% in patients infused with TC-210 and lymphodepletion      – Continued manageable toxicity profile      – Phase 1 trial amended to accelerate treatment– TCR2 to host conference call Monday, December 14 starting at 8:00am E.T. live webcast availableCAMBRIDGE, Mass., Dec. 13, 2020 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced positive interim data from the ongoing Phase 1 portion of the TC-210 ( gavocabtagene autoleucel or “gavo-cel”) Phase 1/2 clinical trial for mesothelin-expressing...

Continue reading

Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA® (Icosapent Ethyl) in Late Breaker Presentation at National Lipid Association (NLA) Scientific Sessions 2020

VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-reactive protein (hsCRP) with encouraging short-term safety and tolerability data using VASCEPA loading doseVASCEPA administration resulted in a significant 52% reduction of the total patient-reported symptom outcome prevalence score as compared to a 24% reduction in the usual care groupLarger follow-on clinical studies have commenced of VASCEPA as a therapeutic option in COVID-19 settings, anticipated to be completed in 2021Amarin to Webcast Discussion of Presented Data on Monday, December 14, 2020 at 8:00 a.m., Eastern Standard TimeDUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 12, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN)...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.